[EN] PYRIMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES [FR] PYRIMIDONES UTILISABLES EN VUE DU TRAITEMENT D'AFFECTIONS ASSOCIÉES AUX CANAUX POTASSIQUES
PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES
申请人:Pfizer Inc.
公开号:EP2619202A1
公开(公告)日:2013-07-31
[EN] PYRIDMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES<br/>[FR] PYRIMIDONES UTILISABLES EN VUE DU TRAITEMENT D'AFFECTIONS ASSOCIÉES AUX CANAUX POTASSIQUES
申请人:PFIZER
公开号:WO2012038850A1
公开(公告)日:2012-03-29
The present invention relates to compounds of Formula I as described herein or a 1 pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.
[EN] PYRIMIDONES FOR TREATMENT OF POTASSIUM CHANNEL RELATED DISEASES<br/>[FR] PYRIMIDONES UTILISABLES EN VUE DU TRAITEMENT D'AFFECTIONS ASSOCIÉES AUX CANAUX POTASSIQUES
申请人:PFIZER
公开号:WO2012038850A8
公开(公告)日:2012-11-01
Pyrimidones for Treatment of Potassium Channel Related Diseases
申请人:Sakurada Isao
公开号:US20130184294A1
公开(公告)日:2013-07-18
The present invention relates to compounds of Formula I as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and methods of treating a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogenital disorders, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.